Clobetasol Propionate
Brand names: Clobetasol Propionate
At a glance
- Medicare prescriptions, 2024
- 2,049,542
- Medicare drug cost
- $96.8M
- Average cost per prescription
- $47.22
- Clinicians who prescribed it
- 48,658
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Clobetasol propionate topical spray, 0.05% is a corticosteroid indicated for the topical treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older Limitations of Use: Do not use on the face, axillae or groin. Do not use if atrophy is present at the treatment site. Do not use for rosacea or perioral dermatitis.
From the FDA-approved prescribing information (label dated July 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Dermatology 39.1%
- Physician Assistants 21.1%
- Nurse Practitioners 12.6%
- Internal Medicine 7.5%
- Family Medicine 7.4%
- OB-GYN (Obstetrics & Gynecology) 5.6%
- Mohs Surgery 1.4%
- Podiatrists 1.1%
- General Practice 0.9%
- Dermatopathology 0.6%
- Urogynecology 0.4%
- Rheumatology 0.4%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 88% from 2019 to 2024.
Biggest change by state since 2019
- Idaho +165%
- Louisiana +150%
- Mississippi +141%
- Minnesota +139%
- Utah +129%
- New Jersey (smallest change) +52%
- Hawaii (smallest change) +59%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
3 recalls since 2020
- Aug 2026 · Lupin Pharmaceuticals Inc. · Class II
Failed content uniformity specifications. - Jan 2023 · Lupin Pharmaceuticals Inc. · Class III
Subpotent Drug: Low assay result observed during long-term stability testing. - Dec 2021 · Taro Pharmaceuticals U.S.A., Inc. · Class I
Microbial Contamination of Non-Sterile Products: presence of R. Pickettii bacteria
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.